| __timestamp | Eli Lilly and Company | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 10337679 |
| Thursday, January 1, 2015 | 6533000000 | 18187286 |
| Friday, January 1, 2016 | 6452000000 | 24758063 |
| Sunday, January 1, 2017 | 6588100000 | 23666957 |
| Monday, January 1, 2018 | 5975100000 | 30099855 |
| Tuesday, January 1, 2019 | 6213800000 | 64947625 |
| Wednesday, January 1, 2020 | 6121200000 | 186363444 |
| Friday, January 1, 2021 | 6431600000 | 272611040 |
| Saturday, January 1, 2022 | 6440400000 | 358782000 |
| Sunday, January 1, 2023 | 6941200000 | 409864000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing the power of data
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Eli Lilly and Company compared to Intra-Cellular Therapies, Inc. over the past decade. From 2014 to 2023, Eli Lilly's SG&A expenses have shown a steady increase, peaking in 2023 with a 5% rise from the previous year. In contrast, Intra-Cellular Therapies, Inc. has experienced a dramatic surge, with expenses growing nearly 40 times from 2014 to 2023. This stark difference highlights Eli Lilly's consistent growth strategy, while Intra-Cellular Therapies is rapidly expanding its market presence. As the pharmaceutical landscape continues to shift, these trends offer valuable insights into the strategic priorities of these industry players.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and PTC Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Cost Management Insights: SG&A Expenses for Zoetis Inc. and Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Intra-Cellular Therapies, Inc. and Alkermes plc
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Intra-Cellular Therapies, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Intra-Cellular Therapies, Inc. vs Perrigo Company plc: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Dynavax Technologies Corporation Trends and Insights